6 completed, 3 recruiting, 2 unknown, 1 active not recruiting. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 6, Recruiting 3, Unknown 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Rectum Cancer: new trials by email Literature Review of Rectum Cancer trials Research Report on Rectum Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients mFOLFIRINOX, mFolfox6 - Rectum Cancer | Phase 2 | Recruiting | Menoufia University | 100 | 2025-01-25 | 2025-02-19 |
| Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine - Colorectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-09-29 | 2024-11-05 |
| SGM-101 in Colorectal Brain Metastases. SGM-101 - Rectal Neoplasms, Rectum Cancer | Phase 2 | Unknown | Leiden University Medical Center | 10 | 2024-01-01 | 2024-05-09 |
| Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) Regorafenib, XmAb20717 - Colorectal Cancer, Colon Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-05-17 | 2024-04-29 | |
| Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Cabozantinib, Nivolumab - Colorectal Adenocarcinoma, Colon Cancer | Phase 2 | Active not recruiting | University of Colorado, Denver | 48 | 2021-06-23 | 2026-03-31 |
| Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer Pembrolizumab - Rectum Cancer, Rectal Cancer | Phase 2 | Recruiting | University Hospital, Geneva | 25 | 2020-06-02 | 2021-09-30 |
| Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum Radiation, Oxaliplatin, Leucovorin - Cancer of Rectum, Cancer of the Rectum | Phase 2 | Completed | Washington University School of Medicine | 20 | 2016-05-27 | 2021-02-18 |
| Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas SGM-101 - Colon Cancer, Rectum Cancer | Phase 1 / Phase 2 | Completed | Surgimab | 75 | 2016-01-01 | 2019-07-18 |
| Effects of S-1 and Capecitabine on Coronary Artery Blood Flow S-1, Capecitabine, Oxaliplatin - Esophagus Cancer, Stomach Cancer | Phase 2 | Terminated | Heikki Joensuu | 20 | 2015-01-01 | 2018-08-28 |
| Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients cetuximab - Rectum Cancer | Phase 2 | Unknown | Copenhagen University Hospital at Herlev | 60 | 2009-08-01 | 2009-08-25 |
| Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum Capecitabine, Oxaliplatin, Bevacizumab - Rectum Cancer | Phase 2 | Completed | Grupo Espanol Multidisciplinario del Cancer Digestivo | 46 | 2009-03-01 | 2013-10-11 |
| Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer Computed tomography guided radioactive seeds implant, Systemic chemotherapy (FOLFIRI) - Rectum Cancer | Phase 2 | Completed | The First People's Hospital of Changzhou | 56 | 2008-10-01 | 2015-04-22 |
| Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer Rapamycin - Rectum Cancer | Phase 1 / Phase 2 | Completed | Maastricht Radiation Oncology | 44 | 2006-09-01 | 2019-03-18 |
| Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy Cetuximab, Irinotecan - Colon Cancer, Rectum Cancer | Phase 2 | Completed | University of Pittsburgh | 35 | 2006-06-01 | 2016-07-12 |
Rectal Neoplasms (14) · Colonic Neoplasms (6) · Colorectal Neoplasms (6) · Gastrointestinal Neoplasms (2) · Brain Diseases (1) · Brain Neoplasms (1) · Esophageal Neoplasms (1) · Gastrointestinal Diseases (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Digestive System Diseases (14) · Digestive System Neoplasms (14) · Neoplasms by Site (14) · Rectal Diseases (14) · Gastrointestinal Diseases (13) · Intestinal Diseases (13) · Intestinal Neoplasms (13) · Neoplasms (13) · Gastrointestinal Neoplasms (12) · Colonic Diseases (8) · Colorectal Neoplasms (8) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Oxaliplatin (3) · Capecitabine (2) · Cetuximab (2) · pembrolizumab (2) · Bevacizumab (1) · Brachytherapy (1) · Cyclophosphamide (1) · Fluorouracil (1) · IFL protocol (1) · Interleukin-2 (1) · Irinotecan (1) · Leucovorin (1) · Neoadjuvant Therapy (1) · Nivolumab (1) · Radiation (1)
Copenhagen University Hospital at Herlev (1) · Essen Biotech (1) · Grupo Espanol Multidisciplinario del Cancer Digestivo (1) · Heikki Joensuu (1) · Leiden University Medical Center (1) · M.D. Anderson Cancer Center (1) · Maastricht Radiation Oncology (1) · Menoufia University (1) · Surgimab (1) · The First People's Hospital of Changzhou (1) · University Hospital, Geneva (1) · University of Colorado, Denver (1) · University of Pittsburgh (1) · Washington University School of Medicine (1)
Netherlands (3) · United States (3) · China (1) · Denmark (1) · Egypt (1) · Finland (1) · Spain (1) · Switzerland (1)
Alex Casalots, Pathologist (1) · Alexander L Vahrmeijer, MD, PhD (1) · Alexis Leal, MD (1) · Ana Darnell, Radiologist (1) · Anna Caltrava, Pathologist (1) · Antonieta Salud, Oncologist (1) · Antonio Lazy, Surgeon (1) · Carles Conill, Radiotherapy (1) · Carles Pericay, Oncologist (1) · Changping Wu, M.D. (1)
PMID 25209376, PMID 29361435, PMID 31960953, PMID 32416765, PMID 34001462, PMID 35840912
P30CA046934 (1)